SciELO - Scientific Electronic Library Online

vol.27 issue2Altas dosis de quimioterapia con trasplante de progenitores hematopoyéticos autólogos en el tratamiento de los tumores del sistema nervioso central en la edad pediátricaTécnicas empleadas para el estudio de la interacción entre agentes antitumorales y el DNA author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Oncología (Barcelona)

Print version ISSN 0378-4835


PEREZ MARTINEZ, A. et al. Altas dosis de quimioterapia y soporte hematopoyético en el tratamiento de niños con meduloblastoma y tumor neuroectodérmico primitivo supratentorial de alto riesgo. Oncología (Barc.) [online]. 2004, vol.27, n.2, pp.24-32. ISSN 0378-4835.

PURPOSE: The combination of high-dose chemotherapy (HDC) and autologous stem cells rescue (ASCR) has been reported as a new relevant treatment improving survival rates of patients with cerebellar medulloblastoma and supratentorial neuroectodermal tumors. We report our preliminary results employing the procedure. MATERIAL AND METHODS: We study 19 patients treated with HDC and ASCR; 13 of them were high risk patients, and 6 had recurrent disease. The patients received granulocyte colony-stimulating factor (G-CSF) at a dose of 12 µg/kg/12 h during four days to stimulate granulocytes proliferation and mobilization. The patients were conditioned with busulfan-melphalan. Additionally, thiotepa was administered to three patients, and topotecan to four. The peripheral blood progenitor cells were collected and infused 48 h after finishing chemotherapy. RESULTS: In an average follow-up of 18 months (range 5-63 months) after transplantation, 9 patients (47%) survived disease-free, 8 with complete remission and 1 with partial remission. Three patients (15%) died due to the toxic effects of the treatment, and 7 (36%) because of disease progression. According to the Kaplan-Meier method, the disease-free survivors were 37.67 ± 14% as a whole, and 57 ± 15% for the high risk patients. CONCLUSIONS: Although the combined use of high-dose chemotherapy and autologous hemopoietic stem cells transplantation is a toxic treatment, in our experience it improves the survival of patients with high risk medulloblastoma and supratentorial primitive neuroectodermal tumors, especially of the later.

Keywords : Peripheral blood progenitor cells; Autologous transplantation; High-dose chemotherapy; High-risk brain tumors; Medulloblastoma; Supratentorial primitive neuroectodermal tumors.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License